Calafiore, Marco
Fu, Ya-Yuan http://orcid.org/0000-0002-3894-0490
Vinci, Paola
Arnhold, Viktor
Chang, Winston Y.
Jansen, Suze A.
Egorova, Anastasiya
Takashima, Shuichiro http://orcid.org/0000-0002-4200-5956
Kuttiyara, Jason
Ito, Takahiro
Serody, Jonathan http://orcid.org/0000-0003-4568-1092
Nakae, Susumu
Turnquist, Heth http://orcid.org/0000-0002-4173-4014
van Es, Johan
Clevers, Hans http://orcid.org/0000-0002-3077-5582
Lindemans, Caroline A.
Blazar, Bruce R.
Hanash, Alan M. http://orcid.org/0000-0002-3273-3634
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01-HL125571, R01-HL146338, R01-HL145631)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30-CA008748)
Article History
Received: 13 March 2023
Accepted: 18 August 2023
First Online: 5 September 2023
Competing interests
: B.R.B. receives remuneration as an advisor to Kamon Pharmaceuticals, Inc, Five Prime Therapeutics Inc, Regeneron Pharmaceuticals, Magenta Therapeutics, and BlueRock Therapeuetics, research support from Fate Therapeutics, RXi Pharmaceuticals, Alpine Immune Sciences, Inc, Abbvie Inc., Leukemia and Lymphoma Society, Childrens’ Cancer Research Fund, and KidsFirst Fund, and is a co-founder of Tmunity. A.M.H. and C.A.L. hold intellectual property related to Interleukin-22, and A.M.H. has a collaboration with Evive Biotechnology (Shanghai) Ltd, which supported a multicenter clinical trial studying use of Interleukin-22 in patients with graft vs. host disease. A.M.H. also serves in a volunteer capacity as a member of the Board of Directors of the American Society for Transplantation and Cellular Therapy (ASTCT). The remaining authors declare no competing interests.